MedTrace Logo

A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)

NCT05596422 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 423

Last updated 2023-01-19

No results posted yet for this study

Summary

This is a non-interventional, retrospective study of adult participants with IBD. IBD consists of either ulcerative colitis (UC) or Crohn's disease (CD). The study will review the clinical data previously collected during February 2007 to March 2020 of approximately 724 participants who have had treatment with adalimumab, infliximab, golimumab, or vedolizumab in Taiwan.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-27
Primary Completion
2022-10-27
Completion
2022-12-08

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05596422 on ClinicalTrials.gov